Severe Hypophosphatemia Following Ferric Carboxymaltose in a Patient With Inflammatory Bowel Disease.

Autor:	Ali A; Gastroenterology, Peterborough City Hospital, Peterborough, GBR., Elmdaah A; Gastroenterology, Peterborough City Hospital, Peterborough, GBR., Mustafa AM; Gastroenterology, Peterborough City Hospital, Peterborough, GBR., Kumaravel Kanagavelu AS; Internal Medicine, Peterborough City Hospital, Peterborough, GBR., Mohamed N; Gastroenterology, Peterborough City Hospital, Peterborough, GBR., Sayed S; Gastroenterology, Peterborough City Hospital, Peterborough, GBR.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2021 Dec 16; Vol. 13 (12), pp. e20452. Date of Electronic Publication: 2021 Dec 16 (Print Publication: 2021).
DOI:	10.7759/cureus.20452
Abstrakt:	Inflammatory bowel disease is a chronic inflammatory condition that affects the large and small bowel, which includes Crohn's disease (CD) and ulcerative colitis (UC). Iron deficiency anemia (IDA) is one of the most common complications in people with inflammatory bowel disease. The treatment of choice is intravenous iron infusion. There is a lack of awareness of side effects of intravenous iron (Ferinject) such as hypophosphatemia, which can prolong hospital admission. We present the case of a patient with iron deficiency anemia and vitamin D deficiency who developed severe hypophosphatemia after intravenous injection of ferric carboxymaltose (Ferinject). In this case presentation, our aim is to increase the awareness of prescribers about the risk of developing low phosphate levels after Ferinject and the need to monitor serum phosphate levels. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2021, Ali et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu